Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have changed the natural history of non-small-cell lung cancer (NSCLC) patients harboring specific EGFR mutations at exons 18, 19 and 21. This evidence concerns the gene EGFR and non-small cell lung carcinoma.